141 related articles for article (PubMed ID: 7209108)
1. [Hydroxyprolinuria in relation to bone metastases in patients with breast cancer].
Rico Lenza H; Millán Núñez-Cortés J; Rodríguez Mora VI; Espinós Pérez D
Rev Esp Oncol; 1980; 27(1):61-6. PubMed ID: 7209108
[TBL] [Abstract][Full Text] [Related]
2. [Hydroxyproline in the diagnosis of bone metastases in breast cancer].
Gasser AB; Depierre D; Alberto P; Courvoisier B
Schweiz Med Wochenschr; 1977 Jul; 107(28):984-6. PubMed ID: 897640
[TBL] [Abstract][Full Text] [Related]
3. [Urinary hydroxyproline excretion before and after hypophysectomy in patients with bone metastases from breast cancer].
Ditzel J; Jordal R; Riskoer N
Ugeskr Laeger; 1968 Oct; 130(42):1766-71. PubMed ID: 5724711
[No Abstract] [Full Text] [Related]
4. Hydroxyproline and zinc excretion in patients with neoplastic breast disease.
Percudani M; Dell'Anna B; De Lorenzis GF; Ferraccioli GF; Vaona GL
Int Surg; 1981; 66(3):233-6. PubMed ID: 7319736
[TBL] [Abstract][Full Text] [Related]
5. Postabsorptive urinary hydroxyproline test in patients with metastatic bone disease from breast cancer.
Niell HB; Palmieri GM; Neely CL; McDonald MW
Arch Intern Med; 1981 Oct; 141(11):1471-3. PubMed ID: 7283558
[TBL] [Abstract][Full Text] [Related]
6. [Urinary hydroxyproline in advanced breast carcinoma and response to treatment with medroxyprogesterone acetate (MAP) in high doses].
Martoni A; Pedelini G; Colalongo G; Biagi R; Mambelli M; Jafelice G; Rocchetta G; Piana E; Pannuti F
Minerva Med; 1980 Sep; 71(31):2215-9. PubMed ID: 7422143
[TBL] [Abstract][Full Text] [Related]
7. Urinary hydroxyproline excretion in patients with breast cancer.
Cuschieri A; Felgate R
Br J Surg; 1971 Nov; 58(11):862. PubMed ID: 5124876
[No Abstract] [Full Text] [Related]
8. [Hydroxyproline excretion as an index for the evaluation of metabolic bone changes].
Mühlbach R
Beitr Orthop Traumatol; 1966 Oct; 13(10):606-8. PubMed ID: 5977397
[No Abstract] [Full Text] [Related]
9. [Use of urinary hydroxyproline excretion as a marker of bone metastases in prostatic cancer (1)].
Kurokawa K; Imai K; Yamanaka H; Tomaru Y; Kitaura K
Hinyokika Kiyo; 1985 Dec; 31(12):2119-25. PubMed ID: 2421558
[TBL] [Abstract][Full Text] [Related]
10. 'Early' breast cancer, bone scanning, and the urinary excretion of hydroxyproline.
Sumner DS; Baum M; Parsons V; Edwards MH
Br J Surg; 1973 Apr; 60(4):306. PubMed ID: 4700234
[No Abstract] [Full Text] [Related]
11. [Urinary hydroxyproline and cancer of the breast].
Bellido V; Carda P; Mascías E
Rev Esp Oncol; 1983; 30(1):7-16. PubMed ID: 6679910
[No Abstract] [Full Text] [Related]
12. The course of the urinary DPD-crosslink secretion in metastatic breast cancer--a possibility for response assessment.
Lüftner D; Günther S; Flath B; Müller C; Echteroff K; Mergenthaler HG; Wernecke KD; Possinger K
Anticancer Res; 1999; 19(4A):2537-44. PubMed ID: 10470191
[TBL] [Abstract][Full Text] [Related]
13. [Variable behavior of urinary hydroxyproline in breast cancer with osseous metastases].
Polico C; Nascimben O; Maccari F; Fazzin G
Quad Sclavo Diagn; 1978 Dec; 14(4):486-93. PubMed ID: 757622
[TBL] [Abstract][Full Text] [Related]
14. [Use of urinary hydroxyproline elimination in the detection of bone metastases secondary to prostatic carcinoma].
de la Peña J; Cárcamo P; Martínez ME; Martínez-Piñeiro JA
Actas Urol Esp; 1983; 7(3):199-204. PubMed ID: 6624563
[No Abstract] [Full Text] [Related]
15. Hydroxyproline excretion in malignant neoplastic disease.
Hosley HF; Taft EG; Olson KB; Gates S; Beebe RT
Arch Intern Med; 1966 Dec; 118(6):565-71. PubMed ID: 5925444
[No Abstract] [Full Text] [Related]
16. Relevance of hydroxyproline excretion to bone metastasis in breast cancer.
Gielen F; Dequeker J; Drochmans A; Wildiers J; Merlevede M
Br J Cancer; 1976 Sep; 34(3):279-85. PubMed ID: 974001
[TBL] [Abstract][Full Text] [Related]
17. Urinary hydroxyproline excretion in carcinoma of the breast.
Cuschieri A; Felgate RA
Br J Exp Pathol; 1972 Jun; 53(3):237-41. PubMed ID: 5055709
[TBL] [Abstract][Full Text] [Related]
18. Urinary excretion of deoxypyridinoline in patients with breast cancer.
Nguyen-Pamart M; Bonneterre J; Hecquet B
Anticancer Res; 1995; 15(4):1601-3. PubMed ID: 7654055
[TBL] [Abstract][Full Text] [Related]
19. Use of an antiosteolytic agent in treatment of patients with bone metastases from breast cancer.
Dady PJ; Coombes RC; Smith IE; Parsons CA; Ford HT; Gazet JC; Henk JM; Nash AG; Powles TJ
Eur J Cancer (1965); 1980; Suppl 1():131-5. PubMed ID: 6459234
[No Abstract] [Full Text] [Related]
20. [Excretion of urinary hydroxyproline in urinary tract diseases].
Guarino A; Comar OB; Taccone W; Cicalese V
Arch Sci Med (Torino); 1979; 136(2):249-54. PubMed ID: 92978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
